
Last update at 2026-06-05T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Thu 15 May 25, 12:06 PMBest Value Stocks to Buy for May 9th
Fri 09 May 25, 09:44 AMFresenius Medical Care AG (FMS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Wed 07 May 25, 07:04 AMFresenius Medical Care First Quarter 2025 Earnings: EPS: €0.52 (vs €0.24 in 1Q 2024)
Wed 07 May 25, 06:03 AMFresenius Medical Care starts 2025 with strong organic revenue and income growth
Tue 06 May 25, 11:00 AMWatch These 3 MedTech Stocks for Q1 Earnings: Beat or Miss?
Mon 05 May 25, 03:09 PMShould You Buy, Sell, or Hold FMS Stock Before Q1 Earnings?
Fri 02 May 25, 03:05 PMFresenius Medical Care (ETR:FME) Will Be Hoping To Turn Its Returns On Capital Around
Sat 26 Apr 25, 06:01 AMWhy Fresenius Medical Care Stock Might be a Great Pick
Thu 17 Apr 25, 12:50 PMVolatile Markets? Try These Relative Price Strength Stocks
Wed 16 Apr 25, 01:07 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 1512.00M | 1056.93M | 1033.02M | 1220.00M | 1572.00M |
| Minority interest | -212.90000M | -202.95700M | -233.46100M | -222.00000M | -250.00000M |
| Net income | 978.00M | 537.91M | 499.00M | 673.00M | 969.00M |
| Selling general administrative | 3032.73M | 2366.29M | 2388.38M | 3784.00M | 3096.00M |
| Selling and marketing expenses | - | 776.53M | 807.96M | - | - |
| Gross profit | 5029.00M | 4756.65M | 4925.01M | 5310.00M | 5077.00M |
| Reconciled depreciation | 1500.41M | 1742.26M | 1751.97M | 1838.36M | 1623.68M |
| Ebit | 1512.00M | 1463.97M | 1457.65M | -258.36300M | 301.32M |
| Ebitda | 2956.96M | 3206.23M | 3209.63M | 1580.00M | 1925.00M |
| Depreciation and amortization | 1444.96M | 1742.26M | 1751.97M | 1838.36M | 1623.68M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 1827.00M | 1392.39M | 1369.44M | -258.36300M | 301.32M |
| Other operating expenses | 17801.00M | 17943.51M | 18084.18M | 18101.00M | 15859.00M |
| Interest expense | 384.41M | 407.04M | 424.64M | 360.00M | 353.00M |
| Tax provision | 320.97M | 316.06M | 300.56M | 325.00M | 353.00M |
| Interest income | 69.61M | 71.58M | 88.22M | 68.00M | 280.00M |
| Net interest income | -314.79800M | -335.46900M | -336.42300M | -292.00000M | -280.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 321.00M | 316.06M | 300.56M | 325.00M | 353.00M |
| Total revenue | 19628.00M | 19335.91M | 19453.62M | 19398.00M | 17619.00M |
| Total operating expenses | 3202.00M | 3364.26M | 3555.57M | 4013.00M | 3317.00M |
| Cost of revenue | 14599.00M | 14579.26M | 14528.61M | 14088.00M | 12542.00M |
| Total other income expense net | -315.00000M | -335.46900M | -336.42300M | 1478.36M | 1270.68M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 1191.27M | 740.87M | 732.46M | 895.00M | 1219.00M |
| Net income applicable to common shares | 978.37M | 537.91M | 499.00M | 673.40M | 969.31M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 31002.00M | 33566.58M | 33929.81M | 35754.00M | 34367.00M |
| Intangible assets | 14826.00M | 1370.08M | 1362.33M | 1518.68M | 1459.39M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1016.00M | 1102.51M | 1326.39M | 351.05M | 342.89M |
| Total liab | 16719.00M | 17798.07M | 19103.27M | 20305.00M | 20388.00M |
| Total stockholder equity | 14283.00M | 14576.56M | 13620.26M | 15449.00M | 13979.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 3310.00M | 3092.67M | 3247.20M | 3393.04M | 3297.44M |
| Common stock | 14283.00M | 293.41M | 293.41M | 293.41M | 293.00M |
| Capital stock | 293.41M | 293.41M | 293.41M | 293.41M | 293.00M |
| Retained earnings | 12207.91M | 11266.29M | 10921.69M | 10711.71M | 10826.14M |
| Other liab | - | - | - | 2661.95M | 2395.14M |
| Good will | 13571.39M | 15170.65M | 14650.01M | 15791.18M | 14361.58M |
| Other assets | 454.77M | 427.83M | 507.53M | 1127.27M | 1239.97M |
| Cash | 1599.00M | 1180.19M | 1403.49M | 1273.79M | 1481.65M |
| Cash and equivalents | 669.42M | 342.86M | 324.43M | 362.77M | 556.52M |
| Total current liabilities | 6245.00M | 5660.06M | 6111.59M | 6467.00M | 7258.00M |
| Current deferred revenue | - | 82.17M | 85.82M | 105.72M | 518.03M |
| Net debt | 9196.00M | 9824.04M | 10673.80M | 11938.78M | 11838.34M |
| Short term debt | 2197.00M | 1218.27M | 1561.56M | 2036.90M | 2585.00M |
| Short long term debt | 1613.04M | 577.38M | 944.60M | 1363.08M | 1924.00M |
| Short long term debt total | 10795.00M | 11004.22M | 12077.29M | 13212.57M | 13320.00M |
| Other stockholder equity | -1591.58600M | 3345.41M | 3380.33M | 4832.35M | 4171.49M |
| Property plant equipment | 6499.80M | 7258.58M | 7454.02M | 8339.81M | 8551.47M |
| Total current assets | 7898.00M | 7922.74M | 8701.41M | 8203.00M | 7967.00M |
| Long term investments | 1323.48M | 1416.69M | 1254.51M | 773.72M | 786.90M |
| Net tangible assets | - | - | - | -3320.40500M | -3122.18700M |
| Short term investments | 238.77M | 163.09M | 154.37M | 169.98M | 136.36M |
| Net receivables | 3142.00M | 3409.03M | 3637.99M | 4031.60M | 3906.68M |
| Long term debt | 5691.85M | 6260.82M | 6959.86M | 7170.73M | 6647.00M |
| Inventory | 2141.00M | 2067.92M | 2179.18M | 2296.21M | 2038.01M |
| Accounts payable | 738.00M | 984.32M | 885.15M | 931.34M | 857.53M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | -328.54500M | -975.16900M | -388.46800M | -1311.63700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 5264.00M | 720.02M | 681.83M | 4967.60M | 5160.73M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 23104.00M | 25643.83M | 25228.40M | 27551.00M | 26400.00M |
| Capital lease obligations | 3490.71M | 4140.70M | 4145.95M | 4678.76M | 4749.00M |
| Long term debt total | 8598.27M | 9760.64M | 10488.85M | 11175.67M | 10734.75M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -4.02400M | -84.93900M | -672.67100M | -734.72500M | -61.57500M |
| Change to liabilities | - | - | - | -356.78900M | -363.95500M |
| Total cashflows from investing activities | -666.17553M | -84.93900M | -544.22700M | -734.72500M | -1196.22800M |
| Net borrowings | 149.58M | -1905.14900M | -1189.79300M | -1023.04500M | -358.90300M |
| Total cash from financing activities | -1375.66436M | -2569.30000M | -1858.52900M | -1617.36000M | -1024.38200M |
| Change to operating activities | - | - | - | 154.03M | 164.20M |
| Net income | 939.75M | 740.87M | 732.46M | 895.00M | 1219.00M |
| Change in cash | 558.32M | -241.89700M | 153.44M | -207.86800M | 400.12M |
| Begin period cash flow | 1040.12M | 1427.22M | 1273.79M | 1481.65M | 1081.54M |
| End period cash flow | 1598.43M | 1185.33M | 1427.22M | 1273.79M | 1481.65M |
| Total cash from operating activities | 2575.19M | 2386.14M | 2628.80M | 2167.00M | 2489.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 1405.66M | 1742.26M | 1751.97M | 1838.36M | 1623.68M |
| Other cashflows from investing activities | -666.17553M | 14.10M | 16.14M | 35.61M | -309.51300M |
| Dividends paid | 405.84M | 349.16M | 328.62M | -395.55600M | -392.45500M |
| Change to inventory | -238.84414M | 107.90M | -13.14000M | -204.30700M | -48.53000M |
| Change to account receivables | -66.33535M | -73.47700M | -151.84400M | -46.68200M | -163.19700M |
| Sale purchase of stock | -562.18538M | 0.00000M | 0.00000M | 20.15M | 6.51M |
| Other cashflows from financing activities | -1174.74013M | -314.98900M | -340.11300M | 1600.22M | 2775.28M |
| Change to netincome | - | - | - | -98.09300M | 32.59M |
| Capital expenditures | 879.24M | 699.36M | 684.60M | 1411.00M | 1683.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 132.78M | 444.31M | 561.28M | -566.00000M | -354.00000M |
| Stock based compensation | - | - | 32.52M | - | -1690.93500M |
| Other non cash items | 123.13M | -468.62400M | -327.27000M | 41.11M | 1624.00M |
| Free cash flow | 1695.95M | 1686.79M | 1944.20M | 756.00M | 806.00M |
Sector: Healthcare Industry: Medical Care Facilities
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| FMS Fresenius Medical Care Corporation |
0.09 0.39% | 22.02 | 11.65 | 9.33 | 0.65 | 0.80 | 1.00 | 5.77 |
| HCA HCA Healthcare, Inc. |
10.30 2.85% | 372.13 | 13.19 | 13.66 | 1.13 | 293.44 | 1.77 | 8.22 |
| FSNUY Fresenius SE & Co KGaA ADR |
0.04 0.37% | 10.75 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| JDHIY JD Health International Inc |
- -% | 5.33 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
| JDHIF JD Health International Inc |
- -% | 5.85 | 57.75 | 32.68 | 0.29 | 2.11 | 0.16 | 3.90 |
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Else-Kröner-Strasse 1, Bad Homburg, Germany, 61352
| Name | Title | Year Born |
|---|---|---|
| Ms. Helen Giza | CEO, Chief Transformation Officer, Acting CFO & Chair of Mgmt Board of Fresenius Med. Care Mgmt AG | 1968 |
| Mr. Robert Maurice Powell Jr. | Member of the Management Board of Fresenius Medical Care Management AG | 1955 |
| Dr. Franklin W. Maddux F.A.C.P. | Global Chief Medical Officer & Member of Management Board of Fresenius Medical Care Management AG | 1957 |
| Mr. William J. Valle | Management Board Member for Care Delivery of Fresenius Medical Care Management AG | 1960 |
| Dr. Katarzyna Mazur-Hofsab Ph.D. | Management Board Member for Care Enablement of Fresenius Medical Care Management AG | 1963 |
| Mr. Roberto Fuste | Exec. Advisor for Regional Strategy | 1952 |
| Dr. Nwamaka Eneanya M.D. | Head of Strategy & Operations | NA |
| Dr. Dominik Heger | Exec. VP and Head of Investor Relations, Strategic Devel. & Communications | NA |
| Mr. Borries Von Muller | Sr. VP of Global HR Employee Communications | 1961 |
| Mr. Joachim Weith | Sr. VP of Corp. Communications & Gov.al Affairs | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.